Ascendis Pharma A (ASND) Net Cash Flow (2014 - 2026)

Ascendis Pharma A has disclosed Net Cash Flow across 13 years of filings, most recently posting -$52.2 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$52.2 million, down 53.35% year-over-year; the trailing twelve-month figure through Mar 2026 was -$96.4 million (down 145.38% YoY), and the FY2025 annual result was -$92.0 million, down 159.54% from the prior year.
• Net Cash Flow came in at -$52.2 million for Q1 2026 at Ascendis Pharma A, up from -$91.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $408.3 million in Q3 2024 to a low of -$169.3 million in Q2 2023.
• The 5-year median for Net Cash Flow is -$68.7 million (2024), against an average of -$24.2 million.
• Across the five-year window, Net Cash Flow plunged 152.93% in 2023 and soared 1912.08% in 2024, its largest moves.
• Ascendis Pharma A's Net Cash Flow stood at -$142.1 million in 2022, then soared by 63.27% to -$52.2 million in 2023, then tumbled by 78.25% to -$93.1 million in 2024, then rose by 1.35% to -$91.8 million in 2025, then surged by 43.18% to -$52.2 million in 2026.
• The last three Net Cash Flow figures came in at -$52.2 million (Q1 2026), -$91.8 million (Q4 2025), and $47.9 million (Q3 2025), per Business Quant data.